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INTRODUCTION
Primary liver cancer, including hepatocellular carcinoma (HCC, 
75–85% of cases), intrahepatic cholangiocarcinoma (10–15% of 
cases), and other rare types, is the sixth most commonly diag-
nosed cancer and the fourth leading cause of cancer-related 
mortality worldwide, as of 2018.1,2 Although the age-standardized 
rate (ASR) of liver cancer has decreased continuously annually 
since 1999, liver cancer is still the sixth most common cancer in 
Korea, with a crude rate of 30.1/100000 and ASR of 17.0/100000, 
which are relatively high, compared with rates seen in other 
countries.3 Moreover, liver cancer is the second most common 
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cause of cancer-related mortality in Korea.4 The mortality rate 
for liver cancer is highest among individuals in their forties and 
fifties, the most economically active working-age population, 
which makes the economic burden of liver cancer highest among 
all cancers.4,5 
Curative treatments for HCC, including hepatic resection, 
liver transplantation, and local ablative therapies, are recom-
mended for early stage HCC and Barcelona Clinic Liver Cancer 
stage A HCC, with a reported median 5-year survival rate of 50% 
to 70% after curative treatments.6-8 Specifically, the 5-year dis-
ease-free survival rate is reportedly 23% to 56.3% after hepatic 
resection and 74% after liver transplantation.6-8 However, most 
patients with HCC are diagnosed at advanced stages, and cu-
rative treatments are occasionally unavailable based on tumor 
size, tumor location, and liver function.6,7,9-11 Therefore, early de-
tection of HCC through cancer surveillance is crucial to imple-
menting curative treatment and improving patient survival. As 
HCC almost exclusively develops in patients with well-known 
risk factors such as chronic hepatitis B virus (HBV) infection, 
chronic hepatitis C virus (HCV) infection, liver cirrhosis, alco-
hol intake, and metabolic disease, HCC surveillance can be ef-
fective.12,13
South Korea launched the National Cancer Screening Pro-
gram for liver cancer in 2003. HCC surveillance is recommended 
in high-risk individuals by several clinical practice guidelines; 
however, surveillance methods, including imaging modality and 
surveillance intervals, vary among the guidelines.14-16 In Korea, 
the National HCC surveillance program conducts serum alpha-
fetoprotein tests and ultrasonography for high-risk people older 
than 40 years who had liver cirrhosis, tested positive for HBV an-
tigen or anti-HCV antibody, or had chronic HBV or HCV liver 
disease. The surveillance interval has remained at 6 months, ex-
cept during 2012–2015, when the surveillance interval changed 
from 6 months to 1 year in Korea. To date, several studies have 
been conducted to evaluate the effectiveness of the surveillance 
program, and most of them have covered data from a single in-
stitution.17-20 In this study, we analyzed associations between 
surveillance intervals and the rates of receiving curative treat-
ment and mortality to evaluate the effectiveness of the national 
HCC surveillance program using nationwide cohort data. 
MATERIALS AND METHODS
Database
The National Health Insurance Service (NHIS) system is a health 
insurance program that covers the entire Korean population. 
In this study, the NHIS-National Health Information Database 
(NHIS-NHID) (NHIS-2020-1-539) was used to retrieve demo-
graphic and medical information of people who were eligible for 
inclusion in the national HCC surveillance program. This data-
base contained not only demographic and socioeconomic data, 
but also healthcare information, including medical history, di-
agnoses, and prescription data. Additionally, we accessed the 
National Liver Cancer Surveillance Program database, which in-
cluded laboratory and ultrasonography results. Furthermore, 
annual reports on the cause of death statistics issued by the Mi-
crodata Integrated Service of Statistics Korea were used to an-
alyze all-cause mortality and its association with surveillance 
intervals.
Study population
The Institutional Review Board of National Health Insurance 
Service Ilsan Hospital approved this study (NHIMC 2020-06-
008). The target population of the national HCC surveillance 
included high-risk people aged ≥40 years who had liver cirrho-
sis, tested positive for HBV antigen or anti-HCV antibody, or had 
chronic HBV or HCV liver disease. The International Classifica-
tion of Diseases-10 codes (ICD-10) was used to identify patients 
who were diagnosed with HCC (ICD-10 code C22.0). Addition-
ally, the NHIS Service code V193, which is applied to patients 
with pathological or radiological diagnosis of cancer who visit-
ed the hospital and underwent medical expense deduction, was 
used to select patients who visited health care institutions for 
HCC treatment.
A flow diagram of patient selection is shown in Fig. 1. Between 
January 2008 and December 2017, 3201852 patients were includ-
ed in the national HCC surveillance program’s target popula-
tion. Among them, 68448 patients visited the hospital for treat-
ment of newly diagnosed HCC (both ICD-10 code C22.0 and 
NHIS code V193) between January 2011 and December 2018 
and were retrospectively registered in this study. After exclud-
ing patients whose income or residential status were unidenti-
fiable (n=3774), 64674 patients were included in the final study 
population, and the following demographic and medical infor-
mation were evaluated: age, sex, income status, residential area, 
disability in the year of HCC diagnosis, liver cirrhosis, alcohol-
related liver disease, HBV, HCV, and Charlson Comorbidity In-
dex (CCI). For CCI, patient comorbidities detected during the 
2 years prior to the diagnosis of HCC were analyzed.21 
Surveillance intervals and curative therapy
We defined the date of HCC diagnosis (the date of the first visit 
to the medical institution with C22.0+V193 codes) as the index 
date and calculated surveillance intervals using the difference 
between the index date and the last surveillance date. Accord-
ingly, surveillance intervals were classified into five groups: nev-
er screened, ≤6 months (6M), 7–12 months (1Y), 13–24 months 
(2Y), and 25–36 months (3Y). 
In this study, we considered that curative therapy was admin-
istered when patients underwent hepatic resection, liver trans-
plantation, or local ablative therapies, including percutaneous 
ethanol injection, radiofrequency ablation, cryoablation, and 
microwave ablation, within 1 year after the diagnosis of HCC.7,22 
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All-cause mortality
Both NHIS data and the causes of death statistics provided by 
the Microdata Integrated Service of Statistics Korea were used 
to identify the deaths of study patients and to calculate all-cause 
mortality from the date of HCC diagnosis to the date of death or 
the end of 2018, whichever occurred first. Meanwhile, early di-
agnosis of cancer due to cancer surveillance can lead to an over-
estimation of prognosis and survival.23 To address lead-time bias, 
the Schwartz formula24 based on tumor volume doubling time 
and tumor diameter can be used. However, these necessary data 
were unavailable from the NHIS-NHID and national liver can-
cer surveillance program database that were used in this study. 
Therefore, we applied two different lead times (157 and 174 days) 
estimated by previous studies to adjust for lead-time bias.24,25 
Statistical analyses
The chi-square test was conducted to compare rates of receiving 
curative therapy and all-cause mortality between the different 
demographic and medical conditions. Odds ratios (ORs) com-
puted by logistic regression were used to investigate the asso-
ciations between the surveillance intervals and curative therapy. 
Additionally, Cox proportional hazards regression was per-
formed to investigate the association between surveillance in-
tervals and all-cause mortality. After univariable analyses of vari-
ous demographic and clinical factors associated with curative 
treatments for HCC and all-cause mortality, multivariable anal-
yses were performed using both logistic regression and Cox 
regression. All statistical analyses were conducted using SAS 
version 9.4 software (SAS Institute, Cary, NC, USA). A p value 
less than 0.05 was considered statistically significant.
RESULTS
Patient characteristics 
Between January 2011 and December 2018, 64674 patients [sex: 
male, 49966 (77.3%); female, 14708 (22.7%); mean age: male, 
60.9±10.0; female, 65.6±10.9] were diagnosed with HCC. The 
patient characteristics of the study cohort are summarized in 
Table 1. Among these patients, 63.4% (40983) of the patients had 
liver cirrhosis, and 53.8% (34823) and 11.1% (7203) had HBV 
and HCV infections, respectively. Patients underwent national 
HCC surveillance for ≤6 months (15587), 7–12 months (6569), 
13–24 months (7383), and 25–36 months (3853) before the di-
agnosis of HCC. Patients who never underwent surveillance 
or received surveillance more than 36 months prior to the di-
agnosis were classified as never screened (31282). 
Association between HCC surveillance and curative 
therapy
In total, 41.6% (26885) of HCC patients received curative therapy. 
Patients in the 6M group (51.9%) received curative therapy more 
often than those in the other surveillance interval groups (1Y, 
48.3%; 2Y, 43.8%; 3Y, 41.3%; and, never screened, 34.5%) (Table 2). 
As shown in Table 2, univariable analysis demonstrated a sig-
nificant association between curative therapy and surveillance 
interval [1Y group: OR, 0.87; 95% confidence interval (CI), 0.82–
0.92; 2Y group: OR, 0.72; 95% CI, 0.68–0.76; 3Y group: OR, 0.65; 
95% CI, 0.61–0.70; never screened: OR, 0.49; 95% CI 0.47–0.51; 
p<0.001]. Likewise, age greater than 60 years, income status, liv-
ing in rural areas, disability, liver cirrhosis, alcoholic liver disease, 
hepatitis infection, and CCI were significantly associated with 
curative therapy in univariable analysis. 
After adjusting for covariates, surveillance interval was still 
found to be significantly associated with curative therapy. The 
adjusted OR for receiving curative therapy decreased as surveil-
lance interval increased (Table 2). Compared to the 6M group, 
the adjusted ORs were 0.87 for the 1Y group (95% CI, 0.82–0.93; 
p<0.001), 0.76 for the 2Y group (95% CI, 0.72–0.81; p<0.001), 0.77 
for the 3Y group (95% CI, 0.71–0.83; p<0.001), and 0.57 for the 
never screened group (95% CI, 0.54–0.59; p<0.001) (Table 2). 
Cirrhotic patients were more likely to receive curative therapy 
than non-cirrhotic patients (OR, 1.11; 95% CI, 1.07–1.15; p<0.001). 
Hepatitis infection was also independently associated with a 
Fig. 1. Flow diagram of patient selection. HCC, hepatocellular carcinoma.
Target population of the national HCC
surveillance program between 2008 and 2017 (n=3201852)
Patients newly diagnosed with HCC and those who visited the hospital 
for cancer treatment between 2011 and 2018 (n=68448)
Final study population (n=64674)
Excluded patients:
- Who were not diagnosed with HCC (n=3103562)
- Who had previous histories of HCC diagnosis (n=29842)
Excluded patients:
- Who had unidentifiable income or residential status (n=3774)
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greater likelihood of receiving curative therapy (hepatitis B: OR, 
1.88; 95% CI, 1.81–1.96; hepatitis C: OR, 1.54; 95% CI, 1.46–1.64; 
co-infection: OR, 1.97; 95% CI, 1.80–2.15; p<0.001). The ORs of re-
ceiving curative therapy were 1.07 (95% CI, 1.02–1.13; p=0.007) 
for CCI 1, 0.67 (95% CI, 0.64–0.70; p<0.001) for CCI ≥2, 0.92 
(95% CI, 0.87–0.98; p=0.004) for the 60–69 year age, 0.55 (95% CI, 
0.52–0.59; p<0.001) for the ≥70 year age, and 1.13 (95% CI, 1.08–
1.19; p<0.001) for disability. Compared to patients with low in-
come, those with middle-high (OR, 1.20; 95% CI, 1.14–1.26; p< 
0.001) and high incomes (OR, 1.43; 95% CI, 1.36–1.50; p<0.001) 
were more likely to receive curative treatment, whereas those 
with medical aid (OR, 0.68; 95% CI, 0.63–0.73; p<0.001) were less 
likely to receive curative treatment (Table 2). 
Association between HCC surveillance and all-cause 
mortality
In total, 43.7% (28279) of the patients died during the follow-
up period. The cumulative mortalities of the 6M, 1Y, 2Y, 3Y, and 
never screened groups were 36.0%, 33.3%, 37.3%, 43.2%, and 
51.4%, respectively (Table 3). Contrary to the rate of receiving 
curative therapy, the association between surveillance interval 
and all-cause mortality was not straightforward and varied. The 
hazard ratios (HR) for the 2Y group (adjusted HR, 1.07; 95% CI, 
1.03–1.12; p=0.003), 3Y group (adjusted HR, 1.14; 95% CI, 1.08–
1.21; p<0.001), and never screened groups (adjusted HR, 1.37; 
95% CI, 1.33–1.42; p<0.001) were significantly greater than those 
of the 6M group (Table 3, Fig. 2). However, the HR of the 1Y group 
(adjusted HR, 0.96; 95% CI, 0.91–1.01; p=0.092) was not signif-
icantly different from that of the 6M group (Table 3). Even af-
ter adjusting for lead-time bias, the 1Y group surveillance inter-
val was significantly associated with a lower risk of all-cause 
mortality than the 6M group surveillance interval (HRs with 157 
days and 174 days of lead time, 0.91; p<0.001) (Table 4, Fig. 2). 
After correction of lead-time bias, the survival benefit of the 2Y 
group was not significantly different from that of the 6M group 
(HRs with 157 days and 174 days of lead time, 1.01; p=0.557 and 
p=0.721).
Patients who received potentially curative therapy were more 
likely to have survival benefits (adjusted HR, 0.26; 95% CI, 0.25–
0.26; p<0.001) than those who did not receive curative therapy 
(Table 3, Fig. 3). The cumulative mortality of the patients who 
received curative therapy was 21.1%, whereas that of patients 
who did not receive curative therapy was 59.8%. A significant 
survival benefit was noted for patients with liver cirrhosis (ad-
justed HR, 0.96; 95% CI, 0.93–0.98; p<0.001) and those with hep-
atitis infection (hepatitis B: adjusted HR, 0.74; 95% CI, 0.72–
0.76; hepatitis C: adjusted HR, 0.81; 95% CI, 0.78–0.84; co–
infection: adjusted HR, 0.73; 95% CI, 0.68–0.78; all p<0.001) 
(Table 3). Significant associations with a survival benefit were 
also observed in the 50–59 years age (adjusted HR, 0.95; 95% CI, 
0.91–0.99; p=0.018), 60–69 years age (adjusted HR, 0.92; 95% 
CI, 0.89–0.96; p<0.001), female (adjusted HR, 0.79; 95% CI, 0.77–
0.81; p<0.001), middle-high income (adjusted HR, 0.94; 95% 
CI, 0.91–0.98; p=0.001), and high income (adjusted HR, 0.83; 
95% CI, 0.80–0.86; p<0.001) (Table 3). On the other hand, an in-
creased risk of mortality was associated with ages ≥70 (adjusted 
HR, 1.29; 95% CI, 1.23–1.34; p <0.001), living in metropolitan ar-
eas (adjusted HR, 1.24; 95% CI, 1.20–1.27; p<0.001), living in ru-

















Capital area 24272 (37.5)
Metropolitan area 16562 (25.6)












Hepatitis B 34823 (53.8)







≤6 months 15587 (24.1)
7–12 months 6569 (10.2)
13–24 months 7383 (11.4)
25–36 months 3853 (6.0)
Never screened 31282 (48.4)
Co-infection, hepatitis B and C infection; CCI, Charlson Comorbidity Index.
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ral areas (adjusted HR, 1.21; 95% CI, 1.18–1.24; p<0.001), dis-
ability (adjusted HR, 1.04; 95% CI, 1.00–1.07; p=0.027), and CCI 
≥2 (adjusted HR, 1.23; 95% CI, 1.19–1.27; p<0.001) (Table 3). 
DISCUSSION
Through this current study of nationwide cohort data, we ana-
lyzed the effectiveness of HCC surveillance and demonstrated 
Table 2. Univariable and Multivariable Analyses of Variables Associated with Curative Therapy for Hepatocellular Carcinoma (HCC) 
Variables Patients* (%)
Univariable analysis Multivariable analysis
OR (95% CI) p value OR (95% CI) p value
Total 26885/64674 (41.6)
Surveillance interval
≤6 months 8095/15587 (51.9) 1.00 1.00
7–12 months 3176/6569 (48.3) 0.87 (0.82–0.92) <0.001 0.87 (0.82–0.93) <0.001
13–24 months 3236/7383 (43.8) 0.72 (0.68–0.76) <0.001 0.76 (0.72–0.81) <0.001
25–36 months 1591/3853 (41.3) 0.65 (0.61–0.70) <0.001 0.77 (0.71–0.83) <0.001
Never screened 10787/31282 (34.5) 0.49 (0.47–0.51) <0.001 0.57 (0.54–0.59) <0.001
Age (yr)
40–49 3574/7453 (48.0) 1.00 1.00
50–59 9974/21310 (46.8) 0.96 (0.91–1.01) 0.087 0.98 (0.93–1.04) 0.513 
60–69 8598/19591 (43.9) 0.85 (0.81–0.90) <0.001 0.92 (0.87–0.98) 0.004
≥70 4739/16320 (29.0) 0.44 (0.42–0.47) <0.001 0.55 (0.52–0.59) <0.001
Sex
Male 20881/49966 (41.8) 1.00 1.00
Female 6004/14708 (40.8) 0.96 (0.93–1.00) 0.036 1.02 (0.98–1.06) 0.336
Income status 
Medical aid 1271/4398 (28.9) 0.63 (0.58–0.68) <0.001 0.68 (0.63–0.73) <0.001
Low 4424/11280 (39.2) 1.00 1.00
Middle-low 4750/11777 (40.3) 1.05 (0.99–1.10) 0.084 1.03 (0.97–1.09) 0.321 
Middle-high 6571/15227 (43.2) 1.18 (1.12–1.24) <0.001 1.20 (1.14–1.26) <0.001
High 9869/21992 (44.9) 1.26 (1.21–1.32) <0.001 1.43 (1.36–1.50) <0.001
Residential area
Capital area 10274/24272 (42.3) 1.00 1.00
Metropolitan area 6952/16562 (42.0) 0.99 (0.95–1.03) 0.477 0.96 (0.93–1.01) 0.090 
Rural area 9659/23840 (40.5) 0.93 (0.90–0.96) <0.001 0.99 (0.95–1.03) 0.584
Disability
None 23015/54942 (41.9) 1.00 1.00
Disabled 3870/9732 (39.8) 0.92 (0.88–0.96) <0.001 1.13 (1.08–1.19) <0.001
Liver cirrhosis
No 9091/23691 (38.4) 1.00 1.00
Yes 17794/40983 (43.4) 1.23 (1.19–1.27) <0.001 1.11 (1.07–1.15) <0.001
Alcoholic liver disease
No 23949/56660 (42.3) 1.00 1.00
Yes 2936/8014 (36.6) 0.79 (0.75–0.83) <0.001 0.98 (0.93–1.03) 0.345
Hepatitis
None 5656/20308 (27.9) 1.00 1.00
Hepatitis B 17412/34823 (50.0) 2.59 (2.50–2.69) <0.001 1.88 (1.81–1.96) <0.001
Hepatitis C 2695/7203 (37.4) 1.55 (1.46–1.64) <0.001 1.54 (1.46–1.64) <0.001
Co-infection 1122/2340 (47.9) 2.39 (2.19–2.60) <0.001 1.97 (1.80–2.15) <0.001
CCI
0 7251/14178 (51.1) 1.00 1.00
1 5829/11478 (50.8) 0.99 (0.94–1.04) <0.001 1.07 (1.02–1.13) 0.007 
≥2 13805/39018 (35.4) 0.52 (0.50–0.54) <0.001 0.67 (0.64–0.70) <0.001
OR, odds ratio; CI, confidence interval; Co-infection, hepatitis B and C infection; CCI, Charlson Comorbidity Index. 
*Data are presented as n1/n (%), where n1 refers to the number of patients who received curative therapy and n refers to the total number of patients in each 
subcategory.  
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Table 3. Univariable and Multivariable Analyses of Variables Associated with All-Cause Mortality 
Variables Patients* (%)
Univariable analysis Multivariable analysis 
HR (95% CI) p value HR (95% CI) p value
Total 28279/64674 (43.7)
Surveillance interval
≤6 months 5608/15587 (36.0) 1.00 1.00
7–12 months 2185/6569 (33.3) 1.01 (0.96–1.06) 0.825 0.96 (0.91–1.01) 0.092
13–24 months 2751/7383 (37.3) 1.18 (1.13–1.24) <0.001 1.07 (1.03–1.12) 0.003
25–36 months 1666/3853 (43.2) 1.35 (1.28–1.43) <0.001 1.14 (1.08–1.21) <0.001
Never screened 16069/31282 (51.4) 1.69 (1.64–1.75) <0.001 1.37 (1.33–1.42) <0.001
Curative therapy   
No 22595/37789 (59.8) 1.00 1.00
Yes 5684/26885 (21.1) 0.22 (0.22–0.23) <0.001 0.26 (0.25–0.26) <0.001
Age (yr)   
40–49 2976/7453 (39.9) 1.00 1.00
50–59 8443/21310 (39.6) 0.99 (0.95–1.03) 0.493 0.95 (0.91–0.99) 0.018 
60–69 7752/19591 (39.6) 1.03 (0.99–1.07) 0.216 0.92 (0.89–0.96) <0.001
≥70 9108/16320 (55.8) 1.74 (1.67–1.81) <0.001 1.29 (1.23–1.34) <0.001
Sex   
Male 22389/49966 (44.8) 1.00 1.00
Female 5890/14708 (40.0) 0.85 (0.82–0.87) <0.001 0.79 (0.77–0.81) <0.001
Income status   
Medical aid 2493/4398 (56.7) 1.22 (1.16–1.28) <0.001 0.99 (0.94–1.04) 0.657
Low 5039/11280 (44.7) 1.00 1.00
Middle-low 5236/11777 (44.5) 0.98 (0.94–1.02) 0.299 0.99 (0.96–1.03) 0.706 
Middle-high 6465/15227 (42.5) 0.92 (0.88–0.95) <0.001 0.94 (0.91–0.98) 0.001 
High 9046/21992 (41.1) 0.85 (0.82–0.88) <0.001 0.83 (0.80–0.86) <0.001
Residential area   
Capital area 9741/24272 (40.1) 1.00 1.00
Metropolitan area 7453/16562 (45.0) 1.18 (1.15–1.22) <0.001 1.24 (1.20–1.27) <0.001
Rural area 11085/23840 (46.5) 1.24 (1.21–1.28) <0.001 1.21 (1.18–1.24) <0.001
Disability   
None 23570/54942 (42.9) 1.00 1.00
Disabled 4709/9732 (48.4) 1.16 (1.12–1.19) <0.001 1.04 (1.00–1.07) 0.027
Liver cirrhosis  
No 10793/23691 (45.6) 1.00 1.00
Yes 17486/40983 (42.7) 0.86 (0.84–0.88) <0.001 0.96 (0.93–0.98) <0.001
Alcoholic liver disease   
No 24188/56660 (42.7) 1.00 1.00
Yes 4091/8014 (51.1) 1.23 (1.19–1.27) <0.001 1.00 (0.97–1.04) 0.996
Hepatitis  
None 11444/20308 (56.4) 1.00 1.00
Hepatitis B 12428/34823 (35.7) 0.49 (0.48–0.51) <0.001 0.74 (0.72–0.76) <0.001
Hepatitis C 3495/7203 (48.5) 0.73 (0.70–0.76) <0.001 0.81 (0.78–0.84) <0.001
Co-infection 912/2340 (39.0) 0.54 (0.51–0.58) <0.001 0.73 (0.68–0.78) <0.001
CCI   
0 4738/14178 (33.4) 1.00 1.00
1 4157/11478 (36.2) 1.08 (1.04–1.13) <0.001 1.03 (0.99–1.07) 0.193 
≥2 19384/39018 (49.7) 1.70 (1.64–1.75) <0.001 1.23 (1.19–1.27) <0.001
HR, hazard ratio; CI, confidence interval; Co-infection, hepatitis B and C infection; CCI, Charlson Comorbidity Index.
*Data are presented as n1/n (%), where n1 refers to the number of deaths and n refers to the total number of patients in each subcategory.
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that a longer surveillance interval was significantly associated 
with a decreased likelihood of receiving curative therapy. HCC 
surveillance programs have been proven to prolong the survival 
of patients with HCC by detecting HCC and increasing the ap-
plication of curative therapies.22,26-32 One of the most important 
factors determining the effectiveness of a surveillance program 
is the selection of an optimal surveillance interval. In this study, 
a linear association was observed between surveillance inter-
val and curative therapy, the most effective surveillance interval 
being 6 months. Similar to our study, Santi, et al.33 compared 
semiannual and annual surveillance and reported that semian-
nual surveillance was superior to annual surveillance in terms 
of early detection of HCC. In addition, Wu, et al.22 demonstrat-
ed that shorter surveillance intervals were associated with the 
probability of receiving curative therapy, although both 6-month 
and 12-month surveillance intervals showed a comparable chance 
of receiving curative therapy. However, reducing the surveillance 
interval to 3 months increased the detection of nonmalignant 
lesions and eventually led to a higher number of unnecessary 
procedures.34 Therefore, in accordance with our study, a surveil-
lance interval of 6 months is considered to be effective in detect-
ing HCC patients who may be candidates for curative therapy. 
We considered hepatic resection, liver transplantation, and 
local ablative therapies performed within 1 year after the diag-
nosis of HCC as curative therapies. These curative therapies led 
to a significantly lower risk (adjusted HR, 0.26) of overall mor-
tality, with a 38.7% reduction in the mortality rate in this study. 
This result was concordant with previous studies that reported 
5-year survival rates of 23–80% after surgical interventions7,8,35,36 
and 40–50% after local ablative therapies.36 Especially, the de-
tection of small HCCs is important because tumor size, partic-
ularly less than 3 cm, is closely related to complete ablation of a 
tumor and, ultimately, a lower rate of local tumor recurrence.37,38
Notably, the 6M group and 1Y group showed comparable all-
cause mortalities in our study, although the former received 
curative therapies more often than the latter, which was sig-
nificantly associated with survival benefits. After adjusting for 
lead-time bias, the HR for the 1Y group was significantly lower 
than that for the 6M group. Adjustment of lead-time bias also 
made the difference between the 6M group and 2Y group insig-
Fig. 2. Kaplan-Meier (KM) survival curves of patients with hepatocellular carcinoma (HCC) stratified according to HCC surveillance intervals. (A) The KM 
survival curve without adjustment for lead-time bias demonstrated that longer surveillance intervals were associated with decreased overall survival, al-
though the ≤6 months and the 7–12 months groups showed no significant difference. (B and C) After adjusting for bias with 157 days (B) and 174 days (C) 
of lead times, the survival benefit of the 7–12 months group became significantly higher than that of ≤6 months group. The difference between the ≤6 
months and the 13–24 months groups became statistically insignificant. 
Table 4. Association between Surveillance Intervals and All-Cause 
Mortality after Adjusting for Lead-Time Bias 
Lead-time
157 days 174 days
HR (95% CI) p value HR (95% CI) p value
Surveillance interval
≤6 months 1.00 1.00 
7–12 months 0.91 (0.87–0.96) <0.001 0.91 (0.86–0.95) <0.001
13–24 months 1.01 (0.97–1.06) 0.557 1.01 (0.96–1.06) 0.721
25–36 months 1.08 (1.02–1.14) 0.008 1.07 (1.01–1.13) 0.014
Never screened 1.28 (1.24–1.32) <0.001 1.27 (1.23–1.31) <0.001
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Fig. 3. Kaplan-Meier (KM) survival curve of patients with hepatocellular 
carcinoma (HCC) depending on curative therapy. The receipt of curative 
therapy was significantly associated with decreased overall survival 
among patients with HCC. Patients who did not receive curative therapy 
within 1 year from the diagnosis of HCC exhibited significantly lower 
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nificant. This discrepancy might be due to various prognostic 
factors that can affect morbidity and mortality after curative ther-
apies. Other than tumor size, another major prognostic factor is 
a patient’s liver function, which is known to influence treatment 
decisions and to be associated with late tumor recurrence after 
resection and all-cause mortality.39-41 Compared to patients with 
normal liver function who can achieve a 5-year survival rate of 
70%, those with portal hypertension show a lower 5-year surviv-
al rate of 50%, which can be even lower in patients with impaired 
liver function.36 Liver cirrhosis, particularly decompensated liver 
cirrhosis, is associated with increased resection-related com-
plications, postoperative liver failure, and mortality.7,13,36,42 In 
Korea, the national HCC surveillance program does not exclude 
patients with severely impaired liver function, namely Child–
Pugh class C, when designating the target population. The se-
verity of liver function in the target population of the national 
HCC surveillance program is an important prognostic factor and 
may lead to results of all-cause mortality that are different from 
those of the chance to receive curative therapies in this study. 
Therefore, even though HCC surveillance with a 6-month sur-
veillance interval can lead to higher rates of curative therapies, 
clinical factors, especially liver function, should be considered 
when evaluating prognosis and patient survival after treatment. 
Unlike most previous observational studies, our study used 
a nationwide cohort, avoided selection bias, and tried to adjust 
for lead-time bias. Furthermore, through comprehensive health 
care information, various demographic and clinical factors, such 
as underlying liver disease and patient comorbidity, were inves-
tigated to correct possible confounding factors that might dis-
turb the effect of HCC surveillance. Nevertheless, some limita-
tions exist in this study. First, calculation of surveillance interval 
based on all surveillance results for the patients was not possi-
ble, because following the surveillance interval strictly is often 
difficult in the real world and the actual time interval between 
surveillance exams can vary. Moreover, we could not identify 
patients who personally underwent cancer screening at their 
own expense. Instead, we used the last surveillance date and 
the date of HCC diagnosis to define the surveillance interval. 
Second, pathological results and imaging data were not obtain-
able to confirm the diagnosis of HCC. Future studies may in-
clude histopathological and imaging data of HCC to analyze 
all-cause mortality or liver-specific mortality because HCC 
prognosis can differ according to histopathologic variants. Al-
though we tried to correct for lead-time bias, HCC surveillance 
might still detect indolent tumors, which would cause lead-
time bias. Forth, since we followed up the patients and evaluat-
ed whether they were diagnosed with HCC or not until the end 
of 2018, patients with less than 3 years of follow-up may be in-
cluded in the final study population, and inclusion of these pa-
tients may cause misclassification bias. Finally, since not all the 
necessary data were accessible, we could not evaluate accurate 
stages of HCC and consider liver function while evaluating all-
cause mortality. 
In conclusion, HCC surveillance, especially at a surveillance 
interval of 6 months, is independently associated with an in-
creased chance of receiving curative therapy. 
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